单位(元)招商国证生物医药指数A(161726)利润表 |
| 报告期 |
2025/6/30 |
2024/12/31 |
2024/6/30 |
2023/12/31 |
| 收入 |
240,657,267 |
-2,817,785,437 |
-3,439,501,620 |
-2,768,919,027 |
| 利息收入 |
735,438 |
2,379,401 |
1,964,826 |
6,471,968 |
| 其中：存款利息收入 |
735,438 |
845,188 |
466,590 |
2,441,527 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益 |
-946,624,604 |
-1,584,379,860 |
-800,225,782 |
-1,067,310,849 |
| 其中：股票投资收益 |
-1,022,228,257 |
-1,739,242,818 |
-908,684,757 |
-1,183,064,056 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
2,032,031 |
7,083,373 |
4,418,986 |
1,362,303 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
73,571,622 |
147,779,585 |
104,039,988 |
114,390,904 |
| 公允价值变动收益 |
1,184,930,130 |
-1,242,712,851 |
-2,642,928,010 |
-1,713,720,436 |
| 汇兑收益 |
- |
- |
- |
- |
| 其他收入 |
1,616,302 |
6,927,872 |
1,687,347 |
5,640,290 |
| 费用 |
57,358,488 |
125,408,150 |
64,313,328 |
167,111,326 |
| 管理人报酬 |
46,547,662 |
101,034,091 |
51,849,496 |
133,943,706 |
| 托管费 |
9,309,532 |
20,206,818 |
10,369,899 |
28,217,959 |
| 销售服务费 |
903,218 |
1,869,969 |
916,711 |
1,981,660 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
597,882 |
2,291,230 |
1,171,621 |
2,953,189 |
| 利润总额 |
183,298,779 |
-2,943,193,587 |
-3,503,814,948 |
-2,936,030,353 |
| 减：所得税费用 |
- |
- |
- |
- |
| 净利润 |
183,298,779 |
-2,943,193,587 |
-3,503,814,948 |
-2,936,030,353 |
*注：新浪财经提醒：以上数据由合作伙伴提供，仅供参考，交易请以正式公告数据为准。
